|
市場調查報告書
藉由生物科技產業新興企業獲得的教訓
Lessons Learned from the Current Crop of Biotech Startups
|
藉由生物科技產業新興企業獲得的教訓 是由出版商Decision Resources, Inc.在2008年08月所出版的。
這份英文市場調查報告書包含40 Pages 價格從美金2250起跳。
本報告書內容包括：生物科技新事業的市場概要及實績、開發中的先導化合物、企業介紹、專家建議等。內容綱要摘記如下：
實施概要
概要
市場動向
Molecure Insight Pharmaceuticals：矚目核心技術
NeurogesX：考慮周邊藥物
NovaBay Pharmaceuticals：鎖定潛在需求
Optimer Pharmaceuticals：發展獨自的預測
Orexigen Therapeutics：發展綜效
Rosetta Genomics：建立符合時宜的夥伴關係
給新成立企業的建議
- 策略選擇：新股票上市前的藍圖規劃
- 與投資人建立關係
- 有力的經營高層
未來預測
專家建議
- 奈米科技：從學術創新到高科技企業
- 從醫療實驗到臨床上的困難
- 將研究成績延伸到研究室之外的方法
- 學術創業家
圖表
Abstract
Introduction
The initial public offering (IPO) market for biotech and specialty pharma
companies has been nearly lifeless in 2008. Investment bankers are unimpressed
by the performance of these companies, and money managers are reluctant to
support a negative trend. The other side of intense pessimism, however, is
that money accumulates on the sidelines where life science investors
ultimately become impatient with money market returns and look for places to
put risk capital to work. We demystify the best way to navigate the startup
route through three in-depth Spectrum Expert Commentaries. A fresh and
comprehensive look at IPOs and industry trends demonstrates that the future is
not all bleak.
Get the Answers You Need to Shape Your Strategy
- Having raised enough money, filed the sufficient forms, and ensured your
leading compound is in the intended phase of development are all important
factors in the decisions companies make before going public. What steps, when
implemented, will further the likelihood of a successful IPO filing? How can
competitors' strategies be interpreted based on their decisions?
- Despite the unstable state of today' s economy, not every startup is aiming
to be acquired by a larger firm. What exit strategies are particularly common
among those biotech startups that are performing well? What motivates the
investors that are observing from the sidelines?
- Expert opinion is unanimous: establishing a strong game plan early in the
process of the pathway to going public - and sticking to it - is essential.
How can a biopharma or diagnostics company looking to invest in a startup
influence that process to create a win-win for all parties involved?
Scope
- Overview of the biotechnology startup landscape: market overview,
market performance, 2007- 2008 IPOs, status of startups' lead compounds in
development.
- Company profiles: detailed company profiles of six startups that
are making strides in today' s tough economy - Molecular Insight
Pharmaceuticals, NeurogesX, NovaBay Pharmaceuticals, Optimer Pharmaceuticals,
Orexigen Therapeutics, and Rosetta Genomics.
- Spectrum Expert Commentaries: in-depth analysis from innovative,
accomplished, and renowned scientist entrepreneurs who provide valuable
strategic insight and advice to early-stage companies.
- Specific insight for young companies: advice on how to plan for the
IPO road show; issues to consider regarding investor relations; and the
advantages of a strong management team.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- State of the Market
- Molecular Insight Pharmaceuticals: Focus on Core Technology
- NeurogesX: Consider the Peripherals
- NovaBay Pharmaceuticals: Target Unmet Need
- Optimer Pharmaceuticals: Offer a Unique Perspective
- Orexigen Therapeutics: Build Synergies
- Rosetta Genomics: Form Timely Partnerships
- Advice to Young Companies
- Choosing a Strategy: The IPO Road Show
- Consider Investor Relations
- Solid Upper Management
- Outlook
Spectrum Expert Commentaries
- Nanotechnology: From Academic Innovations to Cutting-Edge Companies
- Nanotechnology in Medicine
- Nanotechnology for Biotech and Pharma
- BIND and Selecta
- The Trials and Tribulations of Going Public
- One Piece at a Time
- Parting Advice for CEOs of Tomorrow' s Public Companies
- How to Get Your Research Out of the Laboratory:
- A Primer for the Academic Entrepreneur
- Find a Mentor (or Several)
- Document Your Research
- Disclose Early and Often
- “I Don' t Want to Make Money from My Research. I' m a
Scientist.”
- Work with Your Technology Office on the Patent Filing
- Know When Your Technology Is Ready to Be Licensed
- Become Very Familiar with Your Institution' s Conflict of Interest Polices
- Should I License the Technology to an Existing Company or Start a New
Company?
- Licensing to an Existing Company
- Starting a Company Around Your Technology
- What Happens to the Income Generated by the License?
- Getting Started on a Startup
- Make Sure Your Patents Are in Place
- It' s All About the Product!
- Will the Company Be Virtual or Real?
- Will You Work at the Company or Remain in Your Academic Position?
- Form a Team
- Develop a Plan
- How Much Money Do I Need?
- What Kind of Investors Will You Approach?
- Will You Take a Position on the Board of Directors?
- What Are the Most Common Mistakes to Avoid?
- Why Bother?
Tables
- 1. Biotech and Specialty Pharma IPOs, 2007-2008
Figures
- 1. Biotechnology Startups Landscape, 2006-2008
- 2. Development Phase of Biotechnology Companies' Lead Compound, 2006-2008
- 3. Molecular Insight Pharmaceuticals' Pipeline by Phase of Development
- 4. NeurogesX' s Pipeline by Phase of Development
- 5. NovaBay Pharmaceuticals' Pipeline by Phase of Development
- 6. Optimer Pharmaceuticals' Pipeline by Phase of Development
- 7. Orexigen Therapeutics' Pipeline by Phase of Development
- 8. Rosetta Genomics' Diagnostics Pipeline by Phase of Development
|
